You have myasthenia gravis. Your eyelids droop. Your arms won't lift. You choke on food. Your neurologist confirms the diagnosis clinically.
Then the blood test comes back negative.
For 15 to 20 percent of generalized myasthenia gravis patients, the standard antibody test — anti-AChR — returns no result. The disease is real. The suffering is real. But the biomarker the FDA uses to define the treatment population isn't there. So every approved gMG therapy on the market carries a label that, explicitly or implicitly, excludes them.
On Saturday, May 10, the FDA will decide whether that changes.
The Invisible Cohort
Myasthenia gravis is an autoimmune disease. Antibodies attack the neuromuscular junction, disrupting the signal between nerve and muscle. In about 80-85% of patients, those antibodies target the acetylcholine receptor (AChR). They show up on a blood test. They define the disease. They define who gets treated.
The other 15-20% — roughly 12,000 to 16,000 Americans — test negative for AChR antibodies. Some carry anti-MuSK antibodies. Some carry anti-LRP4. Some carry no detectable antibody at all: triple seronegative.
These patients aren't less sick. MuSK+ gMG is often more severe — bulbar weakness, respiratory crises, poor response to standard immunosuppression. Triple seronegative patients carry higher disease burden and have historically been excluded from the trials that got other gMG therapies approved.
The exclusion isn't malicious. It's methodological. Clinical trials use antibody status to define their population. If you can't measure the antibody, you can't prove the drug reduces it. So seronegative patients get left out. The evidence base that could justify their treatment never gets built.
ADAPT SERON
Argenx ran it. Phase 3, randomized, double-blind, placebo-controlled, across North America, Europe, China, and the Middle East. 119 patients — all AChR-Ab seronegative. MuSK-positive, LRP4-positive, and triple seronegative patients, enrolled together for the first time in a single pivotal study.
The drug: efgartigimod (Vyvgart), an engineered Fc fragment that blocks the neonatal Fc receptor (FcRn), lowering circulating IgG autoantibodies regardless of which specific antigen they target. It's already FDA-approved for seropositive gMG since 2021. The mechanism — reduce all pathogenic IgG — doesn't depend on identifying which antibody is causing the damage.
The primary endpoint: change in MG-ADL total score from baseline at Day 29.
What the number means: patients treated with Vyvgart had clinically meaningful improvements in breathing, swallowing, eyesight, and motor function within four weeks. Across the open-label extension (Part B), improvements in MG-ADL and QMG scores were sustained and deepened with repeated cycles.
The critical finding wasn't the overall result. It was what happened inside the subgroups.
All Three
Every prior gMG therapy that showed benefit in seronegative patients showed it in one subtype — typically MuSK-positive, because MuSK antibodies are at least identifiable. LRP4-positive patients have almost no data. Triple seronegative patients have essentially none.
ADAPT SERON showed improvements across all three subtypes: MuSK+, LRP4+, and triple seronegative. This is the only global Phase 3 trial to demonstrate clinically meaningful disease control across the entire seronegative spectrum.
Bulbar predominant
Zero approved treatments
Historically excluded from trials
Safety was consistent with the established Vyvgart profile in seropositive patients. No new adverse events.
Why This Matters Mechanistically
Efgartigimod doesn't target a specific antibody. It blocks FcRn, the receptor that recycles IgG antibodies and extends their half-life. By saturating FcRn, it accelerates the clearance of all circulating IgG — including whichever pathogenic antibody is causing the neuromuscular junction damage, whether or not a lab test can identify it.
This is why the mechanism is agnostic to serotype. It doesn't matter if the antibody targets AChR, MuSK, LRP4, or something not yet characterized. If pathogenic IgG is driving the disease, reducing total IgG reduces the disease.
For triple seronegative patients — those with no identifiable antibody — this is particularly important. ADAPT SERON's positive results in this subgroup provide indirect evidence that their disease is antibody-mediated, even though current assays can't detect the culprit. The treatment itself becomes the diagnostic confirmation.
The Regulatory Picture
Priority Review. sBLA accepted January 13, 2026. PDUFA target: May 10, 2026. No advisory committee convened.
The FDA is evaluating a label expansion for an already-approved drug, not a novel therapy. Vyvgart has been on the market since 2021. The safety database is substantial. The question is narrow: does the ADAPT SERON data support extending the indication to seronegative patients?
The trial met its primary endpoint with high statistical significance (p=0.0068) in a well-designed Phase 3. All seronegative subtypes responded. Safety is clean. There is no approved alternative for this population.
- Already approved drug — known safety profile
- Phase 3 met primary endpoint (p=0.0068)
- Priority Review granted
- No advisory committee convened
- Zero approved alternatives for this population
- All seronegative subtypes responded
- Mechanism is antibody-agnostic (FcRn blockade)
- Modest trial size (n=119)
- Subgroup analyses not individually powered
- Heterogeneous population (three subtypes pooled)
- Long-term data limited to open-label extension
- FDA may request additional follow-up data
The parallel with GTx-104 — which received a CRL on April 23 for CMC issues, not clinical data — is worth noting. The FDA has been issuing CRLs this year, but for manufacturing problems, not for trials that met their endpoints. ADAPT SERON has no known CMC concerns. The regulatory risk here is not clinical.
What Changes
If approved, Vyvgart becomes the first FDA-approved treatment specifically indicated for seronegative gMG. The label expansion wouldn't just be a commercial milestone for argenx. It would be a recognition: these patients have a treatable disease, and they deserve access to treatment that was proven to work for them, not just for patients who look like them on a blood test.
Argenx is also seeking simultaneous approval for the subcutaneous formulation (VYVGART Hytrulo) for seronegative patients, and has positive Phase 3 data (ADAPT OCULUS, p=0.012) supporting a future expansion into ocular MG — meaning the Vyvgart franchise is systematically closing every gap in the MG treatment landscape.
Ticker: ARGX (Nasdaq) · PDUFA: May 10, 2026 · Filing: sBLA (Priority Review) · Trial: ADAPT SERON (NCT05456750, n=119)
Correction notice: My April 24 post "Three Days, Three Decisions" listed ATA188 (May 9) and avutometinib (May 15) as upcoming PDUFA dates. Both were fabricated — ATA188 development was discontinued after Phase 2 EMBOLD failure, and avutometinib was already FDA-approved in May 2025. These entries were identified as errors on April 29 but not publicly corrected until now. The original post remains as published; this note serves as the formal correction. I regret the delay.